Week in Review: JD Health Raises $3.5 Billion in Hong Kong IPO; Climbs 56% on First Day

Deals and Financings   JD Health of Guangzhou , an online healthcare company, raised $3.5 billion in a Hong Kong IPO and rose 56% in its first trading session; Shanghai 's 3D Medicines acquired greater China rights to two novel Sellas cancer immunotherapies in an agreement worth up to $202 million; Nuance Pharma of Shanghai closed a $181 million Series D financing to develop drugs for iron deficiency, pain management and respiratory conditions; Pegbio, a Suzhou biopharma, completed a $122 million financing to support its novel long-acting treatments before its IPO on Shanghai 's STAR market; SciNeuro Pharma, a new Shanghai-Philadelphia company, launched with $100 million in initial funding to develop novel CNS treatments; Jiangsu Wuzhong Pharma out-licensed global ex-China rights for an anti-angiogenesis cancer drug to Denovo Biopharma of Hangzhou and San Diego ; Overland Pharmaceuticals, a Shanghai , Beijing , Boston biopharma, launched with backing from Hillhouse, but few details about its plans; COVID-19 Pandemic Sino Biopharma of Hong Kong will invest $515 million in Beijing 's Sinovac Bio to double production of its inactivated COVID-19 vaccine; Trials and Approvals JW Therapeutics of Shanghai presented positive data from a pivotal trial of its leading CAR-T therapy for patients with B-cell lymphoma; Sinovac Biotech, a Beijing vaccine company, reported China regulators approved its 23-Valent pneumonia vaccine; Shanghai Antengene was approved to start a China Phase III trial of ATG-010 (selinexor), an oral selective inhibitor of nuclear export (SINE); Suzhou Innovent Bio dosed the first patient in a Phase II trial of its CTLA-4 mAb in combination with its anti-PD-1 drug to treat cervical cancer; EOC Pharma, a Shanghai oncology company, was approved to start a China Phase II trial of a novel immunotherapy for breast cancer patients. Stock Symbols: (HK: 6628) (HK:1177) (NSDQ: SVA) (HK: 2126) (HK: 6996) (HK: 01801) Share this with colleagues: // //